Yeah biggest +ve is the throughput increase and biggest negative is the (large) Opex increase. Capex increase expected (Modular units were telegraphed). Early revenue also good. Co products ... ho hum (IMO).
Overall .... good to see further granularity .... but margin (on % basis) has seen some "compression".
- Forums
- ASX - By Stock
- A11
- Ann: Ewoyaa Definitive Feasibility Study
Ann: Ewoyaa Definitive Feasibility Study, page-3
Featured News
Add A11 (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
-0.005(2.33%) |
Mkt cap ! $138.4M |
Open | High | Low | Value | Volume |
21.5¢ | 21.5¢ | 21.0¢ | $10.18K | 48.17K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 44699 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.5¢ | 90 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 44699 | 0.210 |
3 | 26982 | 0.205 |
6 | 160000 | 0.200 |
1 | 15384 | 0.195 |
1 | 50000 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.215 | 90 | 1 |
0.220 | 2439 | 1 |
0.225 | 1341 | 1 |
0.230 | 25000 | 1 |
0.235 | 35352 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
A11 (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online